- Home
- ENSC vs MBIO Comparison
ENSC vs MBIO Comparison
Compare ENSC & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- MBIO
- Stock Information
- Founded
- ENSC 2003
- MBIO 2015
- Country
- ENSC United States
- MBIO United States
- Employees
- ENSC N/A
- MBIO N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- ENSC Health Care
- MBIO Health Care
- Exchange
- ENSC Nasdaq
- MBIO Nasdaq
- Market Cap
- ENSC 5.2M
- MBIO 4.7M
- IPO Year
- ENSC N/A
- MBIO N/A
- Fundamental
- Price
- ENSC $2.15
- MBIO $1.87
- Analyst Decision
- ENSC
- MBIO
- Analyst Count
- ENSC 0
- MBIO 0
- Target Price
- ENSC N/A
- MBIO N/A
- AVG Volume (30 Days)
- ENSC 874.4K
- MBIO 304.1K
- Earning Date
- ENSC 08-13-2025
- MBIO 08-19-2025
- Dividend Yield
- ENSC N/A
- MBIO N/A
- EPS Growth
- ENSC N/A
- MBIO N/A
- EPS
- ENSC N/A
- MBIO N/A
- Revenue
- ENSC $6,224,081.00
- MBIO N/A
- Revenue This Year
- ENSC N/A
- MBIO N/A
- Revenue Next Year
- ENSC $1,381.48
- MBIO N/A
- P/E Ratio
- ENSC N/A
- MBIO N/A
- Revenue Growth
- ENSC 256.35
- MBIO N/A
- 52 Week Low
- ENSC $1.62
- MBIO $0.89
- 52 Week High
- ENSC $14.67
- MBIO $21.95
- Technical
- Relative Strength Index (RSI)
- ENSC 49.40
- MBIO 53.39
- Support Level
- ENSC $1.99
- MBIO $1.41
- Resistance Level
- ENSC $2.25
- MBIO $1.86
- Average True Range (ATR)
- ENSC 0.17
- MBIO 0.17
- MACD
- ENSC -0.00
- MBIO -0.01
- Stochastic Oscillator
- ENSC 47.62
- MBIO 68.21
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.